Case Study: Pfizer achieves CFDA approval for IBRANCE in China with TransPerfect translation support

TransPerfect enables Pfizer to receive CFDA approval for new breast cancer drug

Pfizer engaged TransPerfect (TransPerfect Life Sciences) to support CFDA inspection translations for its breast cancer drug IBRANCE, requiring rapid Chinese↔English turnaround of 2–3 hours. The challenge was multiple simultaneous inspections with different project leads and requestors, creating high coordination and timing pressure to meet regulatory deadlines.

TransPerfect coordinated closely with Pfizer and its production teams, aligning expectations and delivering efficient, high‑quality inspection translations within the required 2–3 hour windows. As a result, Pfizer met all strict inspection timelines and received CFDA approval for IBRANCE in China, enabling timely market access for the drug.

Pfizer